tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Galat A A note on circular-dichroic-constrained prediction of protein secondary structure. 1996 Eur. J. Biochem. pmid:8612612
Márquez JA and Serrano R Multiple transduction pathways regulate the sodium-extrusion gene PMR2/ENA1 during salt stress in yeast. 1996 FEBS Lett. pmid:8612770
Stoller G et al. An 11.8 kDa proteolytic fragment of the E. coli trigger factor represents the domain carrying the peptidyl-prolyl cis/trans isomerase activity. 1996 FEBS Lett. pmid:8612805
Pham SM et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. 1996 J. Thorac. Cardiovasc. Surg. pmid:8614136
Igarashi O et al. B7-1 synergizes with interleukin-12 in interleukin-2 receptor alpha expression by mouse T helper 1 clones. 1996 Eur. J. Immunol. pmid:8617295
Rappersberger K et al. Clearing of psoriasis by a novel immunosuppressive macrolide. 1996 J. Invest. Dermatol. pmid:8618008
Panyi G et al. Immunosuppressors inhibit voltage-gated potassium channels in human peripheral blood lymphocytes. 1996 Biochem. Biophys. Res. Commun. pmid:8619842
Kiang D et al. Cloning the gene encoding Schistosoma mansoni p50, an immunophilin. 1996 Gene pmid:8621074
Wakizaka Y et al. Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. 1996 Transplant. Proc. pmid:8623372
Pan F et al. Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models. 1996 Transplant. Proc. pmid:8623373
Fukushima N et al. Histological findings in heart grafts after orthotopic pig to baboon cardiac transplantation. 1996 Transplant. Proc. pmid:8623400
Takeda M et al. Methotrexate in rescue therapy for xenotransplanted lungs in primates. 1996 Transplant. Proc. pmid:8623402
Andereggen E et al. Immunohistological study of islet xenograft rejection in immunosuppressed recipients. 1996 Transplant. Proc. pmid:8623420
Horimoto H et al. Hepatocyte xenotransplantation for Nagase's analbuminemic rats: the effect of FK506. 1996 Transplant. Proc. pmid:8623421
Sung RS et al. Survival of human islet xenografts irradiated with ultraviolet B in diabetic rats. 1996 Transplant. Proc. pmid:8623427
Pirenne J et al. Addition of the colon to small bowel grafts causes lethal graft-versus-host disease in FK 506-treated pigs. 1996 Transplant. Proc. pmid:8623447
Elmer DS et al. Use of FK506 immunosuppressive therapy in pancreas transplantation. 1996 J Transpl Coord pmid:9188369
Millis JM et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. 1996 Transplantation pmid:8629298
Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. 1996 Arch Dermatol pmid:8629845
DiGiuseppe JA et al. Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia. 1996 Arch. Pathol. Lab. Med. pmid:8629906
Kinoshita I et al. Myoblast transplantation in monkeys: control of immune response by FK506. 1996 J. Neuropathol. Exp. Neurol. pmid:8642394
Singh N et al. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. 1996 Surgery pmid:8644012
Morozumi K et al. Diagnosis of chronic rejection using peritubular and glomerular capillary lesions. 1996 Transplant. Proc. pmid:8644331
Colombani PM et al. Liver transplantation in infants younger than 1 year of age. 1996 Ann. Surg. pmid:8645039
Chudek J et al. [The role of endothelin in the physiology and pathophysiology of the circulatory system and kidneys]. 1996 Pol. Arch. Med. Wewn. pmid:9139279
Osowski CL et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. 1996 Transplantation pmid:8610430
Tanida I et al. Yeast Cls2p/Csg2p localized on the endoplasmic reticulum membrane regulates a non-exchangeable intracellular Ca2+ pool cooperatively with calcineurin. 1996 FEBS Lett. pmid:8566225
Buckle GJ et al. HTLV-I-induced T-cell activation. 1996 J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. pmid:8797712
Platz KP et al. Management of acute steroid-resistant rejection after liver transplantation. 1996 World J Surg pmid:8798364
Min DI et al. Circadian variation of tacrolimus disposition in liver allograft recipients. 1996 Transplantation pmid:8900327
Brazelton TR and Morris RE Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. 1996 Curr. Opin. Immunol. pmid:8902398
Corrigan CJ et al. Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. 1996 Eur. Respir. J. pmid:8902470
Sakane T and Miura K [Research for basic and clinical aspects of Behcet's disease--recent advance and future--]. 1996 Nippon Rinsho pmid:8904250
Weinzweig N et al. Peripheral-nerve allotransplantation in rats immunosuppressed with transient or long-term FK-506. 1996 J Reconstr Microsurg pmid:8905545
Nagai H et al. The role of interleukin-5 (IL-5) in allergic airway hyperresponsiveness in mice. 1996 Ann. N. Y. Acad. Sci. pmid:8906215
Tsunoda SM and Aweeka FT The use of therapeutic drug monitoring to optimise immunosuppressive therapy. 1996 Clin Pharmacokinet pmid:8906895
Hayashi K et al. Suppression of experimental crescentic-type anti-glomerular basement membrane (GBM) nephritis by FK506 (tacrolimus hydrate) in rats. 1996 Jpn. J. Pharmacol. pmid:8822088
Sasahara Y et al. Okadaic acid suppresses neural differentiation-dependent expression of the neurofilament-L gene in P19 embryonal carcinoma cells by post-transcriptional modification. 1996 J. Biol. Chem. pmid:8824230
Lang T et al. Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. 1996 Transplantation pmid:8824477
Matsuda H et al. Interactions of FK506 (tacrolimus) with clinically important drugs. 1996 Res. Commun. Mol. Pathol. Pharmacol. pmid:8824931
Moriwaki A et al. Immunosuppressant FK506 prevents mossy fiber sprouting induced by kindling stimulation. 1996 Neurosci. Res. pmid:8829156
Ankarcrona M et al. Calcineurin and mitochondrial function in glutamate-induced neuronal cell death. 1996 FEBS Lett. pmid:8830666
Alessiani M et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. 1996 Transplantation pmid:8830816
Namieno T and Uchino J Comparative study of the effects of cyclosporine and FK 506 on rat hepatocytes cocultured with nonparenchymal liver cells. 1996 Transplant. Proc. pmid:8908147
Williams R et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. 1996 Transpl. Int. pmid:8959812
Jonas S et al. Indications for tacrolimus anti-rejection therapy in liver allograft recipients. 1996 Transpl. Int. pmid:8959817
James DG A new immunosuppressant: tacrolimus. 1996 Postgrad Med J pmid:8977938
Gruessner RW et al. Use of FK 506 in pancreas transplantation. 1996 Transpl. Int. pmid:8959841
Weppler D et al. Status of liver and gastrointestinal transplantation at the University of Miami. 1996 Clin Transpl pmid:9286568
Fändrich F et al. Circumvention of natural killer cell and T-cell mediated allogeneic target killing with tacrolimus (FK506) in small bowel transplantation related graft-vs-host disease. 1996 Transpl. Int. pmid:8959843
Cooley HM et al. Resolution of pyoderma gangrenosum using tacolimus (FK-506) 1996 Aust N Z J Med pmid:8744629
Antoniou E et al. Effect of RS61443 in combination with leflunomide or FK506 on rat heart allograft survival. 1996 Transpl. Int. pmid:8959858
Golbaekdal K et al. The acute effects of FK-506 on renal haemodynamics, water and sodium excretion and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs. 1996 J. Pharm. Pharmacol. pmid:8961168
Schumacher G et al. Neurologic symptoms improve in patients with Wilson's disease despite immunosuppression. 1996 Transplant. Proc. pmid:8962200
Baruch Y et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. 1996 Transplant. Proc. pmid:8769215
Melter M et al. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. 1996 Transplant. Proc. pmid:8769224
Tanaka M et al. Reduction of immunosuppressive agents after living related donor liver transplantation. 1996 Transplant. Proc. pmid:8769268
Randhawa PS et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. 1996 Am. J. Surg. Pathol. pmid:8772784
Johnson MW et al. Hepatitis C viral infection in liver transplantation. 1996 Arch Surg pmid:8611094
Hisatomi A et al. Effect of Prograf (FK506) on spermatogenesis in rats. 1996 Toxicology pmid:8658548
Laskow DA et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8878381
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. 1996 Transplantation pmid:8878382
Kershner RP and Fitzsimmons WE Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. 1996 Transplantation pmid:8878385
Nolan TJ and Schad GA Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. 1996 Transplantation pmid:8878405
Devine SM et al. Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation. 1996 Bone Marrow Transplant. pmid:8879619
Taylor P et al. Conformational polymorphism in peptidic and nonpeptidic drug molecules. 1996 Biopolymers pmid:9101762
Ikegami S et al. A facilitatory effect on the induction of long-term potentiation in vivo by chronic administration of antisense oligodeoxynucleotides against catalytic subunits of calcineurin. 1996 Brain Res. Mol. Brain Res. pmid:8883951
Soldin SJ Receptor assays in the clinical laboratory. 1996 Clin. Biochem. pmid:8884064
Woodle ES et al. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. 1996 Clin Transplant pmid:8884103
Shapiro R et al. "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. 1996 Transplantation pmid:8932264
Devlin J and Williams R Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. 1996 Transplantation pmid:8932266
Owens-Grillo JK et al. A model of protein targeting mediated by immunophilins and other proteins that bind to hsp90 via tetratricopeptide repeat domains. 1996 J. Biol. Chem. pmid:8662874
Kralli A and Yamamoto KR An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. 1996 J. Biol. Chem. pmid:8663352
Okada K et al. Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. 1996 Ophthalmologica pmid:8738464
Wagner K et al. Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. 1996 Clin. Nephrol. pmid:8738666
Hohage H et al. Influence of cyclosporine A and FK506 on 24 h blood pressure monitoring in kidney transplant recipients. 1996 Clin. Nephrol. pmid:8738668
Herget S et al. Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection. 1996 Clin. Nephrol. pmid:8738671
Alak AM and Lizak PP Quality assurance procedure for monitoring tacrolimus (FK506) concentrations in whole blood by IMx assay. 1996 Ther Drug Monit pmid:8738766
Ockenfels HM et al. Inhibition of T cell cAMP formation by cyclosporin A and FK506. 1996 Naunyn Schmiedebergs Arch. Pharmacol. pmid:8740144
Iwata M et al. Regulation of T cell apoptosis via T cell receptors and steroid receptors. 1996 Stem Cells pmid:8948021
Holt DW et al. Quality assessment issues of new immunosuppressive drugs and experimental experience. 1996 Ther Drug Monit pmid:8857551
McMichael J et al. Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. 1996 Ther Drug Monit pmid:8857564
Bartlett ST et al. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. 1996 Ann. Surg. pmid:8857849
Büttemeyer R et al. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. 1996 Plast. Reconstr. Surg. pmid:8532772
Takuma T et al. Dephosphorylation of cofilin in parotid acinar cells. 1996 J. Biochem. pmid:8864841
Yamada A et al. Long-term acceptance of major histocompatibility complex-mismatched cardiac allograft induced by a low dose of CTLA4IgM plus FK506. 1996 Microbiol. Immunol. pmid:8865157
Christians U et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. 1996 Br J Clin Pharmacol pmid:8866917
[Tacrolimus--a new perspective in kidney transplantation]. 1996 Urologe A pmid:9022401
Iwasaki K et al. Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid. 1996 Res. Commun. Mol. Pathol. Pharmacol. pmid:9029671
Okadome T et al. Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. 1996 J. Biol. Chem. pmid:8702959
Rahfeld JU et al. Isolation and amino acid sequence of a new 22-kDa FKBP-like peptidyl-prolyl cis/trans-isomerase of Escherichia coli. Similarity to Mip-like proteins of pathogenic bacteria. 1996 J. Biol. Chem. pmid:8703024
Pullicino P et al. Posterior leucoencephalopathy syndrome. 1996 Lancet pmid:8684128
Pirenne J et al. Combined transplantation of small and large bowel. FK506 versus cyclosporine A in a porcine model. 1996 Transplantation pmid:8685944
Tsugita M et al. Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. 1996 Transplantation pmid:8685952
Huntress JD and Papadakos PJ The role of calcium-channel antagonists in solid organ transplantation. 1996 New Horiz pmid:8689268
Tokunaga Y and Alak AM FK506 (tacrolimus) and its immunoreactive metabolites in whole blood of liver transplant patients and subjects with mild hepatic dysfunction. 1996 Pharm. Res. pmid:8668663
Dhar DK et al. FK506 maintains cellular calcium homeostasis in ischemia-reperfusion injury of the canine liver. 1996 J. Surg. Res. pmid:8592405
Ueda S et al. In-vitro metabolic studies of tacrolimus using precision-cut rat and human liver slices. 1996 J Pharm Biomed Anal pmid:8951695
Chambraud B et al. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin. 1996 J. Biol. Chem. pmid:8955134
[Transplantation medicine. Tacrolimus increases survival chances after organ transplantation. XVI International Congress of the Transplantation Society. 25-30 August 1996 Barcelona]. 1996 Dtsch. Med. Wochenschr. pmid:9447224